Fate Therapeutics (FATE) Common Equity (2012 - 2026)

Fate Therapeutics (FATE) has 15 years of Common Equity data on file, last reported at $179.7 million in Q1 2026.

• Quarterly Common Equity fell 37.69% year-over-year to $179.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $179.7 million (down 37.69% YoY) and the FY2025 annual result came in at $207.2 million, down 35.0% from the prior year.
• Common Equity slipped to $179.7 million in Q1 2026, from $207.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $633.4 million in Q1 2022 to a low of $179.7 million in Q1 2026.
• A 5-year average of $386.9 million and a median of $397.0 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2024 — Common Equity fell 9.31% — and 2026, when it plunged 37.69%.
• Tracing FATE's Common Equity over 5 years: stood at $483.9 million in 2022, then decreased by 23.87% to $368.4 million in 2023, then slipped by 13.49% to $318.7 million in 2024, then sank by 35.0% to $207.2 million in 2025, then fell by 13.26% to $179.7 million in 2026.
• The last three Common Equity figures came in at $179.7 million (Q1 2026), $207.2 million (Q4 2025), and $234.1 million (Q3 2025), per Business Quant data.